Emergent BioSolutions (EBS) Misses Q3 EPS by 3c, FY Revenue Guidance Beats
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.01 +2.04%
EPS Growth %: -31.3%
Financial Fact:
Earnings per share - basic: 0.52
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -31.3%
Financial Fact:
Earnings per share - basic: 0.52
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.55, $0.03 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $173.7 million versus the consensus estimate of $184.1 million.
GUIDANCE:
Emergent BioSolutions sees FY2018 EPS of $770.00-$800.00, versus the consensus of $741.00.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Q1 EPS miss sends shares down 9% after-hours
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
